Week 8 matt

Day care attendance, presence of siblings, cigarette smoke exposure, lack of breastfeeding, younger age, anatomic malformations, seasonal allergies, and winter months.

Streptococcus pneumoniae.

Methicillin-resistant Staphylococcus aureus.

Respiratory Syncytial Virus (RSV).

Cloudy and bulging tympanic membrane, impaired mobility, and hemorrhagic or moderate/severe erythema of the tympanic membrane.

Antibiotics are indicated when patients exhibit at least two of the following: increased dyspnea, increased sputum volume, or increased sputum purulence.

When patients require mechanical ventilation, whether invasive or non-invasive.

Haemophilus influenzae.

Pseudomonas aeruginosa.

Human rhinovirus.

5-7 days, with outpatients benefiting from shorter courses, typically ≤5 days.

Amoxicillin 1g TID.

To shorten recovery time, reduce the risk of early relapse, and decrease hospital stays.

Rapid onset of otalgia (ear pain).

Doxycycline 100mg BID or Macrolides (Azithromycin or Clarithromycin) in regions with pneumococcal resistance <25%.

Tugging, rubbing, or holding the ear.

Amoxicillin/clavulanate or a Cephalosporin combined with a macrolide or Doxycycline.

Amoxicillin: 80-90 mg/kg/day PO, divided every 12 hours.

Respiratory fluoroquinolones (e.g., Levofloxacin, Moxifloxacin).

Amoxicillin-Clavulanate: 80-90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate.

A Beta-lactam combined with a Macrolide or Respiratory Fluoroquinolones as monotherapy.

Cefdinir, Cefuroxime, Cefpodoxime, Ceftriaxone, Clindamycin.

Vancomycin for MRSA or Piperacillin-Tazobactam for Pseudomonas.

Acetaminophen: 10-15 mg/kg/dose PO every 4-6 hours.

MRSA and Pseudomonas aeruginosa.

Pneumococcal vaccine (PCV 15, PCV 20).

Prednisone 40 mg daily for 5 days.

Vancomycin or Linezolid.

Haemophilus influenzae type b (Hib) vaccine.

The patient’s condition.

5-7 days, with extended durations for MRSA or Pseudomonas infections.

Short-acting beta-agonists (SABA) and short-acting muscarinic antagonists (SAMA).

Annual Influenza vaccine.

Presence of at least two major symptoms or one major and two minor symptoms.

By stimulating beta-2 adrenergic receptors, causing bronchodilation.

Supportive care including analgesics, saline irrigation, and intranasal glucocorticoids.

Rhinosinusitis occurs when sinus openings become blocked, leading to inflammation of the mucosal lining of the nasal passage and paranasal sinuses due to mucus buildup.

They reduce airway inflammation, improve oxygenation, and shorten recovery time.

Allergens, environmental irritants, and infections (viral, bacterial, or fungal).

Oral decongestants, antihistamines, and mucolytics.

It resolves in less than 4 weeks.

Aminopenicillins with clavulanic acid (e.g., Amoxicillin/clavulanate) and macrolides (e.g., Azithromycin).

Amoxicillin-clavulanate (500 mg/125 mg PO TID or 875 mg/125 mg PO BID).

It resolves between 4 and 12 weeks.

It has anti-inflammatory properties and helps reduce airway inflammation and mucus production.

5 - 7 days.

Symptoms persist for more than 12 weeks.

Higher dose amoxicillin-clavulanate, doxycycline, levofloxacin, or clindamycin + cefixime/cefpodoxime in children.

It helps with bronchodilation and has anti-inflammatory properties.

Four or more episodes per year, each separated by at least 10 symptom-free days.

Over-prescription, with 81% of diagnosed adults receiving antibiotics despite most cases being viral.

Oxygen therapy, non-invasive ventilation (NIV), and invasive mechanical ventilation.

Sinusitis occurs due to obstruction of the sinuses, often caused by local edema from an upper respiratory infection or allergies, leading to viscous secretions and decreased mucociliary clearance.

Penicillin-binding protein mutations.

They prevent infections that could lead to COPD exacerbations.

Mild to moderate symptoms including purulent nasal discharge, nasal obstruction, facial pain, headache, ear pain, cough, and fatigue.

Being under 2 or over 65, recently hospitalized, or immunocompromised.

Fever typically resolves within 48 hours.

Less than 10 days with improvement.

More severe symptoms with persistent or worsening fever (≥102°F) for 3-4 days.

Symptoms last more than 10 days or worsen starting around days 5-6.

It focuses on Confusion, Urea levels, Respiratory rate, Blood pressure, and Age (≥65).

The patient can typically be treated as an outpatient.

Hospitalization.

It often results in ICU admission.

When clinical and radiological evidence of pneumonia is present.

Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella species, Staphylococcus aureus, Chlamydia pneumoniae.

Pseudomonas aeruginosa, Staphylococcus aureus (including MRSA), Acinetobacter baumannii, Gram-negative bacilli (e.g., Klebsiella, Escherichia coli).

Prior antibiotic use within 90 days.

They increase the risk for resistant infections, especially in the ICU.

Chronic obstructive pulmonary disease (COPD), heart disease, or structural lung diseases.

CAP is pneumonia that occurs in an outpatient setting or within the first 48 hours of hospital admission, primarily caused by pathogens encountered outside healthcare facilities.

Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae.

Chronic diseases (e.g., heart, lung disease), smoking, and immunosuppression.

HAP occurs 48 hours or more after hospital admission and is not present at the time of admission, often involving multi-drug resistant pathogens.

Pseudomonas aeruginosa, MRSA, and Gram-negative bacteria.

Prior antibiotic use, mechanical ventilation, and prolonged hospitalization.

VAP occurs more than 48 hours after endotracheal intubation and mechanical ventilation, increasing the risk of infection by drug-resistant bacteria.

Similar to HAP, but with a higher risk of resistant organisms like Acinetobacter and Pseudomonas aeruginosa.

They are clinical prediction tools that guide treatment decisions based on patient risk factors and pneumonia severity.

Age, comorbidities, respiratory rate, blood pressure, and level of consciousness.

Patients are classified into five risk classes, with Class I being the lowest risk (typically treated as outpatient) and Class IV or V being the highest risk (often requiring ICU care).